Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4786598
Max Phase: Preclinical
Molecular Formula: C18H27ClN5O9P
Molecular Weight: 523.87
Molecule Type: Unknown
Associated Items:
ID: ALA4786598
Max Phase: Preclinical
Molecular Formula: C18H27ClN5O9P
Molecular Weight: 523.87
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=P(O)(O)C(CO)(CO)OC[C@H]1O[C@@H](n2ncc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O
Standard InChI: InChI=1S/C18H27ClN5O9P/c19-17-22-14(21-9-3-1-2-4-9)10-5-20-24(15(10)23-17)16-13(28)12(27)11(33-16)6-32-18(7-25,8-26)34(29,30)31/h5,9,11-13,16,25-28H,1-4,6-8H2,(H,21,22,23)(H2,29,30,31)/t11-,12-,13-,16-/m1/s1
Standard InChI Key: YWQNNQIKQYXPIC-BRXULGCHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 523.87 | Molecular Weight (Monoisotopic): 523.1235 | AlogP: -0.67 | #Rotatable Bonds: 9 |
Polar Surface Area: 212.54 | Molecular Species: ACID | HBA: 12 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 1.16 | CX Basic pKa: 0.78 | CX LogP: -1.85 | CX LogD: -3.60 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.16 | Np Likeness Score: -0.13 |
1. Du X,Moore J,Blank BR,Eksterowicz J,Sutimantanapi D,Yuen N,Metzger T,Chan B,Huang T,Chen X,Chen Y,Duong F,Kong W,Chang JH,Sun J,Zavorotinskaya T,Ye Q,Junttila MR,Ndubaku C,Friedman LS,Fantin VR,Sun D. (2020) Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production., 63 (18): [PMID:32865411] [10.1021/acs.jmedchem.0c01086] |
Source(1):